SG11201805092WA - Cortistatin analogs and uses thereof - Google Patents
Cortistatin analogs and uses thereofInfo
- Publication number
- SG11201805092WA SG11201805092WA SG11201805092WA SG11201805092WA SG11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- mpk
- quincy
- president
- cambridge
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562387246P | 2015-12-23 | 2015-12-23 | |
US201662297494P | 2016-02-19 | 2016-02-19 | |
PCT/US2016/068125 WO2017112815A1 (en) | 2015-12-23 | 2016-12-21 | Cortistatin analogs and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805092WA true SG11201805092WA (en) | 2018-07-30 |
Family
ID=59091204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805092WA SG11201805092WA (en) | 2015-12-23 | 2016-12-21 | Cortistatin analogs and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (1) | US20180298024A1 (he) |
EP (1) | EP3394072A4 (he) |
JP (1) | JP2019508368A (he) |
KR (1) | KR20180095051A (he) |
CN (1) | CN108699085A (he) |
AU (1) | AU2016377678A1 (he) |
BR (1) | BR112018012647A2 (he) |
CA (1) | CA3009324A1 (he) |
CL (1) | CL2018001733A1 (he) |
CO (1) | CO2018007535A2 (he) |
EA (1) | EA201891511A1 (he) |
IL (1) | IL260123A (he) |
MX (1) | MX2018007804A (he) |
PH (1) | PH12018501351A1 (he) |
RU (1) | RU2018126984A (he) |
SG (1) | SG11201805092WA (he) |
WO (1) | WO2017112815A1 (he) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016287581B2 (en) | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ. ホフマン-ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
KR20210118812A (ko) * | 2018-11-01 | 2021-10-01 | 사이로스 파마수티컬스, 인크. | 시클린-의존성 키나제 7 (cdk7)의 억제제 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2723689C (en) * | 2008-05-05 | 2016-07-05 | Ryan A. Shenvi | Synthesis of (+) cortistatin a and related compounds |
US20110190323A1 (en) * | 2008-08-28 | 2011-08-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses thereof |
US20130217014A1 (en) * | 2012-02-17 | 2013-08-22 | Genentech, Inc. | Methods of using cdk8 antagonists |
WO2014123900A1 (en) * | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
EP3505521A1 (en) * | 2013-12-24 | 2019-07-03 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
-
2016
- 2016-12-21 CA CA3009324A patent/CA3009324A1/en not_active Abandoned
- 2016-12-21 RU RU2018126984A patent/RU2018126984A/ru not_active Application Discontinuation
- 2016-12-21 EP EP16880055.5A patent/EP3394072A4/en not_active Withdrawn
- 2016-12-21 MX MX2018007804A patent/MX2018007804A/es unknown
- 2016-12-21 WO PCT/US2016/068125 patent/WO2017112815A1/en active Application Filing
- 2016-12-21 EA EA201891511A patent/EA201891511A1/ru unknown
- 2016-12-21 AU AU2016377678A patent/AU2016377678A1/en not_active Abandoned
- 2016-12-21 CN CN201680082319.0A patent/CN108699085A/zh active Pending
- 2016-12-21 BR BR112018012647A patent/BR112018012647A2/pt not_active Application Discontinuation
- 2016-12-21 SG SG11201805092WA patent/SG11201805092WA/en unknown
- 2016-12-21 KR KR1020187020634A patent/KR20180095051A/ko unknown
- 2016-12-21 JP JP2018532374A patent/JP2019508368A/ja active Pending
-
2018
- 2018-06-18 IL IL260123A patent/IL260123A/he unknown
- 2018-06-22 CL CL2018001733A patent/CL2018001733A1/es unknown
- 2018-06-22 PH PH12018501351A patent/PH12018501351A1/en unknown
- 2018-06-22 US US16/016,199 patent/US20180298024A1/en not_active Abandoned
- 2018-07-18 CO CONC2018/0007535A patent/CO2018007535A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3009324A1 (en) | 2017-06-29 |
CO2018007535A2 (es) | 2018-07-31 |
IL260123A (he) | 2018-07-31 |
EA201891511A1 (ru) | 2018-12-28 |
PH12018501351A1 (en) | 2019-02-27 |
KR20180095051A (ko) | 2018-08-24 |
AU2016377678A1 (en) | 2018-07-12 |
CL2018001733A1 (es) | 2018-11-09 |
RU2018126984A (ru) | 2020-01-23 |
US20180298024A1 (en) | 2018-10-18 |
CN108699085A (zh) | 2018-10-23 |
EP3394072A4 (en) | 2019-05-29 |
MX2018007804A (es) | 2019-07-04 |
BR112018012647A2 (pt) | 2018-12-04 |
EP3394072A1 (en) | 2018-10-31 |
JP2019508368A (ja) | 2019-03-28 |
WO2017112815A1 (en) | 2017-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201805092WA (en) | Cortistatin analogs and uses thereof | |
SG11201804161VA (en) | Compositions comprising bacterial strains | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
SG11201804363UA (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201407268SA (en) | Nuclear transport modulators and uses thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900689RA (en) | Compounds and compositions and uses thereof | |
SG11201805001UA (en) | Method of treating influenza a |